Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CAR-T update

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 28, 2024 8:55pm

137 Views

Post# 36245708

RE:RE:RE:RE:CAR-T update

16th Annual International Oncolytic Virotherapy

MECHANISM OF ACTION
16:00 - 16:30 hrs	Title to be announced by Richard Vile, Professor (Mayo Clinic, USA)

Conference 27 – 30 October 2024 - Rotterdam, the Netherlands

Monday October 28, 2024 - 09:30-10:30 am - Plenary Presentation Session 1 - Intravenous Pelareorep Combined with the PD-L1 Inhibitor Atezolizumab Demonstrates Promising Efficacy in Pancreatic and Anal Cancer in the Phase 1/2 GOBLET Study (by Thomas Heinemans)

https://iovc2024.nl/program-sponsors/

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing